Ramón
García Sanz
Profesor Titular de Universidad
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (45)
2023
-
Characterization of the first HLA-DQA1 allele with Aspartic Acid in the transmembrane domain, HLA-DQA1*05:71
HLA, Vol. 102, Núm. 3, pp. 381-383
-
Detection and characterization of the novel HLA-DPA1*02:66:02N allele, with a premature stop codon in exon 2
Human Immunology, Vol. 84, Núm. 4, pp. 296-300
-
Identification of the novel HLA-DQA1*01:04:07 allele with a synonymous substitution and an intronic insertion
HLA, Vol. 101, Núm. 5, pp. 559-561
-
Identification of two novel HLA-DQB1*03:01:01 intronic variants: HLA-DQB1*03:01:01:47 and -DQB1*03:01:01:48
HLA, Vol. 101, Núm. 5, pp. 562-564
-
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655
-
The novel HLA-DQB1*03:02:01:14 allele was possibly generated by a recombination event
HLA, Vol. 102, Núm. 2, pp. 258-260
-
Transitions in intronic regions result in two novel HLA-DQB1 alleles: –DQB1*05:02:01:13 and -DQB1*05:02:01:14
HLA, Vol. 102, Núm. 2, pp. 260-262
2022
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
Experimental Hematology and Oncology, Vol. 11, Núm. 1
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 7, pp. 4171-4182
2019
-
Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas
Blood Cancer Journal, Vol. 9, Núm. 7
-
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
Blood Cancer Journal, Vol. 9, Núm. 12
2018
-
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility
Haematologica, Vol. 103, Núm. 5, pp. 880-889
2017
-
Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma
Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615
-
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
Journal of Hematology and Oncology, Vol. 10, Núm. 1
2016
-
High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma
Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262